GSV Ophthalmics Pvt. Ltd. Balance Sheet as at Mar 31,2023 (Amount in INR, unless otherwise stated)

Particulars		As at	As at
ASSETS	Notes	31 March 2023	31 March 2022
Non-current assets			
Capital work-in-progress			
Other non-current assets		12,28,930	12,28,930
Total Non-current Assets	4	2,08,75,685	4,11,73,307
Total Hori-culteric Assets		2,21,04,615	4,24,02,237
Current Assets			
Financial Assets			
Cash and cash equivalents	1 - 1]	
Bank balances other than cash and cash equivalents	5	37,276	5,73,279
Other Current assets	6	11,75,00,000	9,92,00,000
Total Current Assets	7	1,14,18,799	60,05,290
Total Assets		12,89,56,075	10,57,78,569
•		15,10,60,690	14,81,80,806
EQUITY AND LIABILITIES			
Equity			
Equity share capital			
Other equity	8	14,71,00,000	14,71,00,000
Total equity	9	20,94,990	(7,64,598)
		14,91,94,990	14,63,35,402
iabilities			
current liabilities	1 1		
urrent liabilities			
Trade payables			
i) total outstanding dues of micro enterprises and small enterprises	10		
ii)total outstanding dues of creditors other than micro enterprise and small			
ther current liabilities		67,500	18,45,404
otal current liabilities	11	17,98,200	
otal liabilities		18,65,700	18,45,404
		18,65,700	18,45,404
otal equity and liabilities			
		15,10,60,690	14,81,80,806

As per our report of even date

Dinesh Heda

Chartered Accountants Membership No. 48860

UDIN: 23048860BGZGVA2740

Dinesh Heda Proprietor

Membership No. 48860

Place: Mapusa - Goa Date: 25 May, 2023 For and on behalf of the Board of Directors GSV Ophthalmics Private Limited

CIN: U36990GA2018PTC013725

K.G. GUPTA Managing Director

DIN: 00051863

Place: Mapusa - Goa Date: 25 May, 2023 Cedric Lobo Director DIN: 09124746

Place: Mapusa - Goa Date: 25 May, 2023

Statement of Profit and Loss for the year ended Mar 31, 2023

(Amount in INR, unless otherwise stated)

Particulars	Notes	Year ended	Year ended
Income	Notes	31 March 2023	31 March 2022
Revenue from operations			
Other income	42	_	
Total income	12	76,46,974	50,70,436
	1 1	76,46,974	50,70,436
Expenses			
Finance costs	13	4 207	
Depreciation and amortization expense	14	1,297	1,331
Other expenses	14	5,37,795	5,37,794
Total expenses	" -	12,31,658	19,30,751
		17,70,750	24,69,876
Profit / (Loss) before exceptional items and tax		50.74.224	
exceptional items		58,76,224	26,00,560
Profit / (Loss) before tax		F0 7/ 22/	
ax expense		58,76,224	26,00,560
Current tax		17.09.200	
Deferred tax		17,98,200	
otal income tax expense	-	17,98,200	
A CONTRACTOR AND ADDRESS OF THE ADDR	1 -	17,96,200	
rofit / (Loss) for the year		40,78,024	2/ 00 5/0
20 02 V		40,70,024	26,00,560
ther comprehensive income for the period, net of tax		-	
			•
otal comprehensive income for the period		40,78,024	24 00 E40
		10,70,024	26,00,560
arnings per equity share			
Basic		0.28	0.33

As per our report of even date

SH HED

M. NO. 048860

CHARTERED ACC

Dinesh Heda

Chartered Accountants Membership No. 48860 UDIN: 23048860BGZGYA2740 For and on behalf of the Board of Directors of

GSV Ophthalmics Private Limited CIN: U36990GA2018PTC013725

Dinesh Heda

Proprietor

Membership No. 48860

Place: Mapusa - Goa Date: 25 May, 2023 K.G. GUPTA Managing Director

DIN: 00051863

Place: Mapusa - Goa Date: 25 May, 2023 Cedric Lobo Director DIN: 09124746

Place: Mapusa - Goa Date: 25 May, 2023

(A) Equity share capital

Particulars	31-Mar-23		31-Mar-22	
Equity shares of Rs. 10 each issued, subscribed and fully paid	No. of shares	Amount	No. of shares	Amount
Opening Add: issue during the period	1,47,10,000	14,71,00,000	1,47,10,000	14,71,00,000
Closing	1,47,10,000	14,71,00,000	1,47,10,000	14,71,00,000

(B) Other equity

For the period ended Mar 31, 2022

Particulars	Balance as at April 01, 2021	Total Comprehensive Income/(Loss) for the quarter		Dividends	Others	Balance as at Mar 31, 2022
Reserves Retained earnings	(33,65,158)	26,00,560	-	-		(7,64,598)
Total reserves	(33,65,158)	26,00,560	-			(7.64.598)

For the Period ended Mar 31, 2023

Particulars		Total Comprehensive Income/(Loss) for the quarter	Dividends	Others	Balance as at Mar 31, 2023
Reserves Retained earnings	(7,64,598)	40,78,024			33,13,426
Total reserves	(7,64,598)	40,78,024	-		33,13,426

As per our report of even date

Dinesh Heda

Chartered Accountants Membership No. 48860

UDIN: 23048860BGZGVA2740

&SH HEDA

CHARTERED AC

Dinesh Heda Proprietor

Membership No. 48860

Place: Mapusa - Goa Date: 25 May, 2023 For and on behalf of the Board of Directors of GSV Ophthalmics Private Limited

CIN: U36990GA2018PTC013725

K.G. GUPTA Managing Director DIN: 00051863

Place : Mapusa - Goa

Date: 25 May, 2023

Cedric Lobo Director DIN: 09124746

MAPUSA

Place : Mapusa - Goa

Date: 25 May, 2023

GSV Ophthalmics Pvt. Ltd. Statement of cash flows for the year ended Mar 31, 2023 (Amount in INR, unless otherwise stated)

Particulars	Year ended	Year ended
Cash flow from operating activities	31 March 2023	31 March 2022
Profit / (Loss) before the and a transfer		
Profit / (Loss) before tax and extraordinary items Adjustments for:	40,78,024	26,00,56
Depreciation and amortization expenses		20,00,50
Capital Advance Written off	5,37,795	5,37,79
Interest on lease deposit	10,00,000	5,57,77
Interest income	(2,79,029)	(2,54,12
med est modifie	(55,67,945)	(48,16,31
Add:- Provision for Tax	(2,31,155)	(19,32,08)
Operating Profit / (Loss) before working capital	12,18,436	
changes		
	9,87,281	(19,32,082
Changes in working capital		
Increase / (Decrease) in trade and other payables		
(Increase) / Decrease in other current assets	(17,77,904)	17,94,000
(Increase) / Decrease in other current assets	(54,13,509)	(2,58,386
Cash generated used in operations	17,98,200	(1,125
STATE COST III OPELACIOIS	(44,05,932)	(3,97,593
Income tax paid		(37,37,333
Net cash flows used in operating activities (A)	-	
in operating activities (A)	(44,05,932)	(3,97,593
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets Proceeds from sale / disposal of fixed assets		(12,28,930)
ayment of capital advances	1	(
ayment of security deposit	2,05,36,501	5,99,439
Purchase)/Sale of current investments	2,79,029	-,.,,.,
nterest received	(1,83,00,000)	10,00,000
let cash flow from investing activities (B)	13,54,399	3,95,313
Tom mesung activities (b)	38,69,929	7,65,822
ash flow from Financing activities		.,,
roceeds from issuance of equity shares		
et cash flow from financing activities (C)		
to cash now from financing activities (C)	-	
et increase in cash and cash equivalents (A+B+C)	(5,36,003)	3,68,229
	(-,,,	3,00,229
ash and cash and allow the transfer of the tra	5,73,279	2,05,050
ash and cash equivalents at the beginning of the year	3,0,2,7	2,03,030
ash and cash equivalents at the end of the year	37,276	5,73,279
	57,270	3,73,279
lances with banks		
On current accounts	37,276	5,73,279
	. , , , ,	3,73,279
tal cash and bank balances at end of the year	37,276	5,73,279

The accompanying notes are an integral part of the financial statements.

M.NO.04886

CHARTERED ACCO

As per our report of even date

Dinesh Heda

Chartered Accountants

Membership No. 48860

UDIN: 23048860BGZGVA2740 HED

Dinesh Heda Proprietor

Membership No. 48860

Place: Mapusa - Goa Date: 25 May, 2023 For and on behalf of the Board of Directors of

GSV Ophthalmics Private Limited CIN: U36990GA2018PTC013725

K G GURTA

K.G. GUPTA Managing Director DIN: 00051863

Place : Mapusa - Go Date : 25 May, 2023 Cedric Lobo Director DIN: 09124746

MAPUSA IM Place : Mapusa - Goa Date : 25 May, 2023

MICS PA

GSV Ophthalmics Pvt. Ltd. Notes forming part of the Financial Statements for the period ended Mar 31, 2023 (Amount in INR, unless otherwise stated)

4	OTHER NON-CURRENT ASSETS	31 March 2023	31 March 2022
	Capital advance		
	Capital advance Security deposits	95,00,000	3,00,36,501
	Rent paid in advance	31,26,264	28,47,235
	Advance income tax	65,93,507	76,69,096
	Advance income tax	16,55,914	6,20,475
		2,08,75,685	4,11,73,307
5	CASH AND CASH EQUIVALENTS	24 House 2022	
		31 March 2023	31 March 2022
	Balances with banks:		
	On current accounts	37,276	F 72 270
	Cash on hand	37,276	5,73,279
		37,276	5,73,279
6	BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS In Fixed deposit with maturity for more than 3 months but	31 March 2023	31 March 2022
	less than 12 months from balance sheet date	11,75,00,000	9,92,00,000
		11,75,00,000	9,92,00,000
7	OTHER CURRENT ASSETS	31 March 2023	31 March 2022
	Advances to suppliers (Considered good)		
	Prepaid expenses	F 37 70 /	60,018
	Interest accrued on fixed deposits	5,37,794	
	Input credit receivable	1,05,87,365	56,51,632
		2,93,640	2,93,640
		1,14,18,799	60,05,290





Notes forming part of the Financial Statements for the period ended Mar 31, 2023

(Amount in INR, unless otherwise stated)

8 SHARE CAPITAL

EQUITY SHARES Authorized	31 March 2023	31 March 2022
[3,00,00,000 equity shares (31 March 2021: 3,00,00,000 equity shares) of Rs. 10 each]	30,00,00,000	30,00,00,000
Issued, subscribed and paid up	30,00,00,000	30,00,00,000
[1,47,10,000 equity shares (31 March 2021: 1,47,10,000 equity shares)of Rs. 10 each fully paid	14,71,00,000	14,71,00,000
Subscribed and Paid up :		
[1,47,10,000 equity shares (31 March 2021: 1,47,10,000 equity shares) of Rs. 10 each fully paid	14,71,00,000	14,71,00,000
	14,71,00,000	14,71,00,000

(a) Reconciliation of equity shares outstanding at the beginning and at the end of the year

	31 March 2023		31 March 2022	
Equity Character at the best of the	Number of shares	Amount	Number of shares	Amount
Equity Shares at the beginning of the year	1,47,10,000	3,01,00,000	1,47,10,000	3,01,00,000
Add: Issued during the year		11,70,00,000	, ., , . , . ,	3,01,00,000
Equity Shares at the end of the year	1,47,10,000	14,71,00,000	1,47,10,000	3,01,00,000

(b) Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having par value of Rs. 10 per share. Each shareholder is entitled to one vote per share held. Dividend if any declared is payable in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares

(c) Details of shares held by shareholders holding more than 5% of the aggregate shares in the Company

Name of the shareholder	31 March	2023	31 March 2022	
Equity shares of Rs. 10 each fully paid	Number of shares	% of holding in the class	Number of shares	% of holding in the class
GKB Ophthalmics Ltd. Sanjiv Kumar Gupta Lalit Kumar Gupta	1,17,00,000 15,00,000 15,00,000	79.54% 10.20% 10.20%	1,17,00,000 15,00,000 15,00,000	79.54% 10.20% 10.20%

- (d) No class of shares have been issued as bonus shares or for consideration other than cash by the Company during the period of five years immediately preceding the current year end.
- (e) No class of shares have been bought back by the Company during the period of five years immediately preceding the current year end.

9 OTHER EQUITY

(C) Surplus/(deficit) in the Statement of Profit and Loss	31 March 2023	31 March 2022
Opening balance Add/ (Less): Profit / (Loss) for the current period Add/(Less): Re-measurement gain / (loss) on post employment benefit obligation (net of tax) Closing balance	(7,64,598) 28,59,588	(33,65,158) 26,00,560
	20,94,990	(7,64,598)





Notes forming part of the Financial Statements for the period ended Mar 31, 2023

(Amount in INR, unless otherwise stated)

Total outstanding dues of micro enterprises and small enterprises

Total outstanding dues of creditors other than micro enterprises and small enterprises

67,500	18,45,404
67,500	18,45,404

Disclosure relating to suppliers registered under MSMED Act based on the information available with the Company:

Particulars	31 March 2023	34 Hareh 2022
(a) Amount remaining unpaid to any supplier at the end of each accounting period:	31 Mai Cii 2023	31 March 2022
Principal		
Interest		
Total		
(b) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year.		
(c) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act. (d) The amount of interest accrued and remaining unpaid at the end of each accounting year.		
(e) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act.		

11 Other current liabilities

Statutory due payable Provision for Income tax (Net of Tax paid) Advance from related party

31 March 2023	31 March 2022
	-
17,98,200	
17,98,200	





Notes forming part of the Financial Statements for the period ended Mar 31, 2023 (Amount in INR, unless otherwise stated)

12 Other income	31 March 2023	31 March 2022
Interest income		
- on fixed deposits	FF (7.0.F	
- on lease deposits	55,67,945	48,16,311
- Liabilities written back	2,79,029	2,54,125
The state of the s	18,00,000	
	76,46,974	50,70,436
13 Finance costs	31 March 2023	31 March 2022
Bank charges	1,297	1,331
	1,297	1,331
14 Depreciation and amortization expense	31 March 2023	24 Harab 2022
	31 March 2023	31 March 2022
Depreciation		121
Amortization	5,37,795	5,37,794
	5,37,795	5,37,794
14 Other expenses	31 March 2023	31 March 2022
Dates and T		
Rates and Taxes	1,300	15,630
Travelling and conveyance		
Printing & Stationery		*
Legal and professional charges	1,12,471	90,556
Audit fees (refer foot note 1) Rent	22,500	22,500
	•	18,00,000
Capital advances written off	10,00,000	
Miscellaneous expenses	95,387	2,065
	12,31,658	19,30,751
Foot note 1:		
The following is the break-up of Auditors remuneration (exclusive of GST).		
	31 March 2023	31 March 2022
As auditor:		
Statutory audit	22,500	22,500
Total	22,500	22,500





GSV Ophthalmics Pvt. Ltd. Notes forming part of the Financial Statements for the period ended Mar 31, 2023 (Amount in INR, unless otherwise stated)

15 Earnings/ Loss per share

Basic earnings /(loss) per share amounts are calculated by dividing the profit/loss for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

The following reflects the income and share data used in the basic EPS computations:

Loss attributable to equity holders	31 March 2023	31 March 2022
1 A D D D D D D D D D D D D D D D D D D	40,78,024	26,00,560
Weighted average number of equity shares for basic EPS* Basic loss per share (INR)	1,47,10,000	78,16,027
basic toss per share (INK)	0.28	0.33

16 5-4	31 March 2023	31 March 2022
16 Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances paid)	3,14,82,352	3,20,26,352

17 Related Party Disclosures

(A) Names of related parties and description of relationship as identified and certified by the

Parent Company
GKB Ophthalmics Ltd.

Associates / Enterprises in which Directors exercise significant influence

GKB Vision Private Limited GKB Vision FZC GKB Ophthalmics Products FZE Lensco-The Lens Company

Key Management Personnel (KMP)

Mr. K G Gupta

Mr. Prakash Joshi

Mr. Cedric Lobo (w.e.f. 5th April 2021)

Non-Executive Director

Additional Director

(B) Details of transactions with related party in the ordinary course of business for the year ended:

(i) Parent Company	31 March 2023	31 March 2022
Re-imbursement of expenses	1,20,133	1,54,488
Payment of lease deposit		1,08,00,000
Proceeds received from Issue of share capital Lease rent expense		8,70,00,000
Lease rent expense	1,80,00,000	
Total	1,81,20,133	9,79,54,488

(D) Terms and conditions of transactions with related parties

Outstanding balances at the year-end are unsecured and interest free and settlement mostly occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the year ended 31 March 2022, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (31 March 2021: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.



- 18 The products manufactured by the company do not have a warranty period, hence provision for warranty as specified in Indian Accounting Standard (Ind AS) 37 on "Provisions, Contingent Liabilities and Contingent Assets" is not required to be made.
- 19 During the year the Company has not capitalised any borrowing costs as per Ind AS 23 "Borrowing costs".
- 20 In the opinion of the Board, the Current assets and loans and advances are approximately of the value stated, if realized in the ordinary course or business, except otherwise stated. The provision for all the known liabilities is adequate and not in excess of amount considered reasonably necessary.
- 21 Previous year figures have been regrouped/ reclassified to confirm presentation as per Ind AS as required by Schedule III of the Act.

As per our report of even date Dinesh Heda **Chartered Accountants**

Membership No. 48860 UDIN: 23048860BGZGVA2740

SH HEDA

Proprietor Membership No. 48860

Place: Mapusa - Goa Date: 25 May, 2023

For and on behalf of the Board of Directors of **GSV Ophthalmics Private Limited**

CIN: U36990GA2018PTC013725

K.G. GUPTA Managing Director

DIN: 00051863

Place: Mapusa - Goa

Date: 25 May, 2023

Cedric Lobo Director DIN: 09124746

Place: Mapusa - Goa

Date: 25 May, 2023

GOA